Antiangiogenic effects of zoledronate on cancer neovasculature

被引：2

作者：

Metcalf, Stephen ^{[1
]}

Pandha, Hardev S. ^{[1
]}

Morgan, Richard ^{[1
]}

机构：

[1] Univ Surrey, Fac Hlth & Med Sci, Postgrad Med Sch, Guildford GU2 5XH, Surrey, England

来源：

FUTURE ONCOLOGY | 2011年 / 7卷 / 11期

关键词：

angiogenesis; cancer; neovasculature; zoledronate; BISPHOSPHONATE-RELATED OSTEONECROSIS; METASTATIC COLORECTAL-CANCER; REFRACTORY PROSTATE-CANCER; RENAL-CELL CARCINOMA; PHASE-II TRIAL; BREAST-CANCER; ENDOTHELIAL-CELLS; BONE METASTASES; ANGIOGENIC FACTORS; MULTIPLE-MYELOMA;

D O I：

10.2217/FON.11.113

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Angiogenesis, one of the hallmarks of cancer, supplies nutrients to cancerous tissues to facilitate rapid growth. Targeting cancer-associated angiogenesis is an important goal in cancer therapy and there are currently many drugs that affect tumor-associated vasculature. In this article, we will focus on the antiangiogenic effects of zoledronate (ZA), a bisphosphonate drug routinely used in the treatment of cancer-associated bone disease. This article covers the known effects of ZA throughout the clinical process. It also covers the animal models of cancer that have been treated with ZA and evaluated for angiogenesis, concluding with the current clinical data pertaining to angiogenic factors after ZA treatment.

引用

页码：1325 / 1333

页数：9

共 68 条

[1] Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice [J].

Aharinejad, S ;

Paulus, P ;

Sioud, M ;

Hofmann, M ;

Zins, K ;

Schäfer, R ;

Stanley, ER ;

Abraham, D .

CANCER RESEARCH, 2004, 64 (15) :5378-5384

[2] Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: Role of bone marrow-derived myelomonocytic cells [J].

Ahn, G-One ;

Brown, J. Martin .

CANCER CELL, 2008, 13 (03) :193-205

[3] In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates [J].

Aparicio, A ;

Gardner, A ;

Tu, Y ;

Savage, A ;

Berenson, J ;

Lichtenstein, A .

LEUKEMIA, 1998, 12 (02) :220-229

[4] Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? [J].

Ayllon, J. ;

Launay-Vacher, V. ;

Medioni, J. ;

Cros, C. ;

Spano, J. P. ;

Oudard, S. .

ANNALS OF ONCOLOGY, 2009, 20 (03) :600-601

[5]

Bäckman U, 2008, ANTICANCER RES, V28, P1551

[6] Drug-Induced Vessel Remodeling in Bone Metastases as Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging and Vessel Size Imaging: A Longitudinal In vivo Study [J].

Baeuerle, Tobias ;

Merz, Maximilian ;

Komljenovic, Dorde ;

Zwick, Stefan ;

Semmler, Wolfhard .

CLINICAL CANCER RESEARCH, 2010, 16 (12) :3215-3225

[7] Accumulation of VEGFR2 in zoledronic acid-treated endothelial cells [J].

Basi, David L. ;

Lee, Soo Woon ;

Helfman, Sarah ;

Mariash, Ami ;

Lunos, Scott A. .

MOLECULAR MEDICINE REPORTS, 2010, 3 (03) :399-403

[8] Zoledronate inhibits αvβ3 and αvβ5 integrin cell surface expression in endothelial cells [J].

Bellahcene, A. ;

Chaplet, M. ;

Bonjean, K. ;

Castronovo, V. .

ENDOTHELIUM-JOURNAL OF ENDOTHELIAL CELL RESEARCH, 2007, 14 (02) :123-130

[9] Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis [J].

Bergers, G ;

Brekken, R ;

McMahon, G ;

Vu, TH ;

Itoh, T ;

Tamaki, K ;

Tanzawa, K ;

Thorpe, P ;

Itohara, S ;

Werb, Z ;

Hanahan, D .

NATURE CELL BIOLOGY, 2000, 2 (10) :737-744

[10] Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death -: Evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt [J].

Bezzi, M ;

Hasmim, M ;

Bieler, G ;

Dormond, O ;

Rüegg, C .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (44) :43603-43614

← 1 2 3 4 5 6 7 →